PUBLIC COMPANY
save$IBRXImmunityBio, Inc.
$IBRX10.29+10.83%San Diego, CA, USupdated 1d ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 31pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis
- phase1A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
- phase2N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
- phase2Immunotherapy Before and After Surgery
- phase2HCW9218 for Advanced Pancreatic Cancer
- phase3ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
- phase3Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
- phase3ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC
🐶 Hiring Signal
next earnings Nov 3, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that